Tag Archive: vaccine manufacture

  1. Professor Tomáš Hanke speaks to Scientia about innovative methods in vaccine design and development to combat HIV.

    Leave a Comment

    Prof Hanke, EAVI2020 PI at the University of Oxford spoke to Scientia which included his work on T cell response to second-generation conserved immunogen, HIVconsvX, and its predecessor, HIVconsv. Scientia is a popularised outreach journal that provides researchers with a platform to communicate their findings to others outside their speciality. Technical nomenclature is often transcribed into easier formats allowing further reach of the scientific outputs for maximising social impact, and engaging stakeholders.

    Read the full article at the Scientia website.

    Professor Tomáš Hanke – Use of Experimental Medicine for Rational Development of an Effective HIV Vaccine

    Aug 12, 2020 | BiologyHealth and Medicine

    Reference
    https://doi.org/10.33548/SCIENTIA538

    screenshot of Scientia article on website

  2. A vaccine revolution. Where do we begin?

    Leave a Comment

    EAVI2020 coordinator, Prof Robin Shattock lead the recent Imperial Global Science Policy Forum which focussed on global challenges surrounding vaccines and the latest research in vaccine technology.

    EAVI coordinator, Prof Robin Shattock presented at the recent Imperial Global Science Policy Forum in May 2019; a high-profile network which hosts a programme of events focussing on some of the most important global challenges. The theme for this iteration focussed on contemporary challenges of vaccine development.

    “Vaccination is one of the most effective medical interventions ever introduced”

    Prof. Robin Shattock

    As director of the Future Vaccine Manufacturing Research (FMV) Hub, which is looking to transform how we manufacture vaccines for developing countries, Robin spoke about the main challenges in the current landscape, which include antibiotic resistance, cost of manufacturing, and public awareness and push back. This led to a mapping of the strategies FMV Hub have put in place to tackle these challenges. He detailed how a revolutionary model of vaccine development and distribution – a hub-and-spoke model as a simplified description – will produce benefits and impact from global to local levels.

    Robin sitting with three other people while a crowd ask questions in the Q&A session

    “Rise in antibiotic resistance is increasingly becoming a problem”.

    Prof Robin Shattock

    Robin was joined by fellow researchers from Imperial also bringing forth their innovative studies to vaccine development, Professor Wendy Barclay from Virology and Professor Jason Hallet from Natural Resource Engineering. The presentations were delivered in PechaKucha format; a simple presentation style where the images advance automatically after 20 seconds and presenters talk along to the images. This was effective and connected the audiences to the content and to each speaker.

    “Vaccine discovery and development is a very risky business…[but] we are already beginning to make a difference in vaccine technology”

    Prof Robin Shattock
    Robin sitting with three other people while a crowd ask questions in the Q&A session
    [From left] Prof Danny Altmann (chair), Prof Robin Shattock, Prof Jason Hallett, and Prof Wendy Barclay

    Robin thus gave a speedy but succinct 6-minute presentation on the establishment of international collaborations aimed to accelerate the search for an effective HIV vaccine. Much like the work going on in EAVI2020 this involves preclinical identification, development and selection of HIV microbicide and vaccine candidates.

    Go to the website for more information on the strategies, impact and benefit of the Future Vaccine Manufacturing Research (FMV) Hub.